glp-1 cigna coverage will stop covering weight-loss drugs including Wegovy and Zepbound in its ​employee health plan effective July 1, according to Reuters Online Weight Loss Covered by

There are some very clear side effects and adverse events and they occur at quite shocking rates

From an HbA1c at baseline of 8.7% (72 mmol/mol), the active treatment led to a reduction in HbA1c to 7.37.6% (5660 mmol/mol) depending on the dosage, which was 0.71% (710 mmol/mol) lower than the control group

I marknadsfringa av et kosttilskot er det ikkje lov vise til dokumentert effekt

Given the challenges obesity poses in this fieldincluding increased perioperative risk, altered musculoskeletal biomechanics, and poorer long-term outcomesGLP-1 agonists may play a valuable role in optimizing orthopedic surgical care

Accordingly, the bulk of the clinical evidence of the effects of the drug class on HF have been collected in the placebo-controlled CVOTs in people with type 2 diabetes and established CVD or CVD risk (Table 1) (Sattar et al., 2021)

While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy